T1	Participants 85 192	Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy
T2	Participants 352 476	patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy
T3	Participants 868 965	1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy
T4	Participants 1933 2053	patients with metastatic non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy
T5	Participants 2114 2148	patients with squamous cell tumors
T6	Participants 2173 2189	elderly patients
T7	Participants 2230 2349	patients with tumors harboring epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations
